financetom
Business
financetom
/
Business
/
MPLX Q1 Net Income, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MPLX Q1 Net Income, Revenue Rise
Apr 30, 2024 6:09 AM

08:42 AM EDT, 04/30/2024 (MT Newswires) -- MPLX LP ( MPLX ) reported Q1 net income Tuesday of $0.98 per diluted unit, up from $0.91 a year earlier.

Analysts polled by Capital IQ expected $0.96.

Revenue and other income for the quarter ended March 31 was $2.85 billion, up from $2.71 billion a year earlier.

Four analysts surveyed by Capital IQ expected $2.90 billion.

Price: 42.25, Change: +0.29, Percent Change: +0.69

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Market Chatter: Intel Expected to Receive $3.5 Billion From US Government to Develop Chips for Military
Update: Market Chatter: Intel Expected to Receive $3.5 Billion From US Government to Develop Chips for Military
Mar 8, 2024
07:08 AM EST, 03/08/2024 (MT Newswires) -- (Updates with Intel's ( INTC ) response in the fourth paragraph and the latest stock movement in the fifth paragraph.) Intel ( INTC ) is expected to receive $3.5 billion from the US government to develop advanced semiconductors for military and intelligence programs, Bloomberg reported late Wednesday, citing congressional aides. The financing is...
Algonquin's Q4 Adjusted EPS Drops YOY; Decides To Not Provide Not Adjusted EPS Guidance for 2024
Algonquin's Q4 Adjusted EPS Drops YOY; Decides To Not Provide Not Adjusted EPS Guidance for 2024
Mar 8, 2024
07:12 AM EST, 03/08/2024 (MT Newswires) -- Algonquin Power & Utilities Corp. ( AQNB ) reported Friday an adjusted EPS of US$0.16 in the fourth quarter of 2023, rising year over year from US$0.14. Revenue fell to US$666.9 million from US$748.0 million and adjusted EBITDA grew 13% to US$334.3 million. For full-year 2023, Algonquin's adjusted EPS fell 13% to US$0.53...
--Wedbush Raises On Holding's PT to $38 From $33, Says 'Brand Heat Remains Extremely Strong,' Maintains Outperform Rating
--Wedbush Raises On Holding's PT to $38 From $33, Says 'Brand Heat Remains Extremely Strong,' Maintains Outperform Rating
Mar 8, 2024
07:10 AM EST, 03/08/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us) Price: 32.2, Change: +0.18, Percent Change: +0.56 ...
Amylyx's ALS drug fails in late-stage confirmatory study
Amylyx's ALS drug fails in late-stage confirmatory study
Mar 8, 2024
March 8 (Reuters) - Amylyx Pharmaceuticals ( AMLX ) said on Friday its drug to treat a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal in a late-stage confirmatory study. The company said its plans for the drug may include voluntarily withdrawing it from the market. (Reporting by Mariam Sunny in Bengaluru; Editing by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved